Lack of effect of the dopamine D1 antagonist, NNC 01-0687, on unstimulated and stimulated release of anterior pituitary hormones in males

Journal of Endocrinological Investigation

Volumn 21, Issue 5, 1998, Pages 291-297

  Grodum, E ^a   Andersen, M ^a   Hangaard, J ^a   Koldkjaer, O ^b   Hagen, C ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Soenderborg Sygehus   (Denmark)

Author keywords

Anterior pituitary hormones; Dopamine; Dopamine D1 antagonist

Indexed keywords

5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 8 NITRO 1H 3 BENZAZEPIN 7 OL; DOPAMINE 1 RECEPTOR BLOCKING AGENT; FOLLITROPIN; GROWTH HORMONE; HYPOPHYSIS HORMONE; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE; THYROID HORMONE; THYROTROPIN;

ADENOHYPOPHYSIS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLITROPIN RELEASE; GROWTH HORMONE RELEASE; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE RELEASE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROLACTIN RELEASE; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE RELEASE; THYROID HORMONE RELEASE; THYROTROPIN RELEASE;

EID: 0031746597     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350331     Document Type: Article

References (39)

1. Leebaw W.F., Lee L.A., Woolf P.D. Dopamine affects basal and augmented pituitary hormone secretion. J. Clin. Endocrinol. Metab. 47: 480, 1978.
2. Santen R.J., Bardin C.W. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. J. Clin. Invest. 52: 2617, 1973.
3. Strange P.G. New insights into dopamine receptors in the central nervous system. Neurochem. Int. 22: 223, 1993.
4. Kebabian J.W. Brain dopamine receptors: 20 years of progress. Neurochem. Res. 18: 101, 1993.
5. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature 277: 93, 1979.
6. Creese I., Sibley D.R., Leff S.E. Agonist interactions with dopamine receptors: focus on radioligand-binding studies. Fed. Proc. 43: 2779, 1984.
7. Boesgaard S., Hagen C., Andersen A.N., Eldrup E., Lange P. Effect of fenoldopam, a dopamine D-1 receptor agonist, on pituitary, gonadal and thyroid hormone secretion. Clin. Endocrinol. (Oxf.) 30: 231, 1989.
8. Hagen C., Andersen A.N., Djursing H. Evidence of altered dopaminergic modulation of PrI, LH, FSH, GH and TSH secretion during chronic partial dopamine receptor blockade in normal women. Acta Endocrinol. (Copenh.) 106: 1, 1984.
9. Andersen P.H., Gronvald F.C. Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivo [published erratum appears in Life Sci 1986, Sep 22; 39 (12): 1117]. Life Sci. 38: 1507, 1986.
10. Andersen P.H., Nielsen E.B. The dopamine D1 receptor: biochemical and behavioral aspects. Adv. Exp. Med. Biol. 204: 73, 1986.
11. Monsma F.J. Jr., Mahan L.C., McVittie L.D., Gerfen C.R., Sibley, D.R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. U.S.A. 87: 6723, 1990.
12. Sibley D.R., Monsma F.J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13: 61, 1992.
13. Boesgaard S., Hagen C., Hangaard J., Andersen A.N., Eldrup, E. Effect of dopamine and a dopamine D-1 receptor agonist on pulsatile thyrotrophin secretion in normal women. Clin. Endocrinol. (Oxf.) 32: 423, 1990.
14. Denef C., Tilemans D., Andries M. Paracrine control in the anterior pituitary: Growth factors from gonadotrophs control DNA replication in lactotrophs, somatotrophs and corticotrophs. In: Faglia G., Beck-Peccoz P., Ambrosi B., Travaglini P., Spada H., (eds.), Pituitary adenomas: new trends in basic and clinical research. Elsevier Science Publisher BV, 49, 1991 (Abstract).
15. Nielsen E.B., Andersen P.H. Dopamine receptor occupancy in vivo: behavioral correlates using NNC-112, NNC-687 and NNC-756, new selective dopamine D1 receptor antagonists. Eur. J. Pharmacol. 219: 35, 1992.
16. Skrumsager B.K., Christensen J.V., Snel S., Seiberling M. Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects. Psychopharmacology (Berlin) 121: 294, 1995.
17. Christensen J.V. Determination of (+)-5-(2,3-dihydrobenzofuran-7-yl) -3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol (NNC 01-0687), a novel dopamine D-1 receptor antagonist, in plasma by solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. 577: 366, 1992.
18. Fuxe K., Agnati L.F., Anderson K., Eneroth P., Haerfstrand A., Goldstein M. The external layer of the median eminence and the paraventricular hypothalamic nucleus represent two important levels of integration in the neuroendocrine regulation. Studies on peptide-catecholamine interactions give evidence for the existence of "mediasomes". In: del Pozo E., Flückiger E. (eds.), Dopamine and Neuroendocrine Substances. Academic Press Inc. Ltd., London, 1985, p. 11.
19. James M.D., MacKenzie F.J., Tuohy Jones P.A., Wilson C.A. Dopaminergic neurones in the zona incerta exert a stimulatory control on gonadotrophin release via D1 dopamine receptors. Neuroendocrinology 45: 348, 1987.
20. Shupnik M.A., Greenspan S.L., Ridgway E.C. Transcriptional regulation of thyrotropin subunit genes by thyrotropin-releasing hormone and dopamine in pituitary cell culture. J. Biol. Chem. 261: 12675, 1986.
21. Agner T., Hagen C., Andersen A.N., Djursing H. Increased dopaminergic activity inhibits basal and metoclopramide-stimulated prolactin and thyrotropin secretion. J. Clin. Endocrinol. Metab. 62: 778, 1986.
22. Delitala G. Dopamine and TSH secretion in man [letter]. Lancet 2: 760, 1977.
23. Brabant G., Prank K., Hoang Vu C., Hesch R.D., von zur Muhlen A. Hypothalamic regulation of pulsatile thyrotropin secretion. J. Clin. Endocrinol. Metab. 72: 145, 1991.
24. Kerr D.J., Singh V.K., McConway M.G., Beastall G.H., Connell J.M., Alexander W.D., Davies D.L. Circadian variation of thyrotrophin, determined by ultrasensitive immunoradiometric assay, and the effect of low dose nocturnal dopamine infusion. Clin. Sci. 72: 737, 1987.
25. Samuels M.H., Henry P., Ridgway E.C. Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J. Clin. Endocrinol. Metab. 74: 217, 1992.
26. Burrow G.N., May P.B., Spaulding S.W., Donabedian R.K. TRH and dopamine interactions affecting pituitary hormones secretion. J. Clin. Endocrinol. Metab. 45: 65, 1977.
27. Rossmanith W.G., Mortola J.F., Laughlin G.A., Yen S.S. Dopaminergic control of circadian and pulsatile pituitary thyrotropin release in women. J. Clin. Endocrinol. Metab. 67: 560, 1988.
28. Hagen C., Petersen K., Djursing H., Andersen A.N. Evidence of altered dopaminergic modulation of PrI, LH and TSH secretion in patients with normoprolactinaemic amenorrhoea. Acta Endocrinol. (Copenh.) 106: 8, 1984.
29. Martin W.H., Rogol A.D., Kaiser D.L., Thorner M.O. Dopaminergic mechanisms and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women. J. Clin. Endocrinol. Metab. 52: 650, 1981.
30. Halse J., Harris A.G., Kvistborg A., Kjartansson O., Hanssen E., Smiseth O., Djosland O., Hass G., Jervell J. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J. Clin. Endocrinol. Metab. 70: 1254, 1990.
31. Yamada M., Monden T., Satoh T., Lizuka M., Murakami M., Iriuchijima T., Mori M. Differential regulation of thyrotropin-releasing hormone receptor mRNA levels by thyroid hormone in vivo and in vitro (GH3 cells). Biochem. Biophys. Res. Commun. 184: 367, 1992.
32. Jones K.E., Chin W.W. Differential regulation of thyroid hormone receptor messenger ribonucleic acid levels by thyrotropin-releasing hormone. Endocrinology 128: 1763, 1991.
33. Philip F., Baxter J.B., Frohman L.A. (eds.). Endocrinology and Metabolism. New York: McGraw-Hill, INC. 1995.
34. Andersen A.N., Hagen C., Lange P., Boesgaard S., Djursing H., Eldrup E., Micic S. Dopaminergic regulation of gonadotropin levels and pulsatility in normal women. Fertil. Steril. 47: 391, 1987.
35. Yen S.S., Quigley M.E., Reid R.L., Ropert J.F., Cetel N.S. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am. J. Obstet. Gynecol. 152: 485, 1985.
36. Lamberts S.W. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors Endocr. Rev. 9: 417, 1988.
37. Skrumsager B.K., Christensen J.V., Karlson P., Farde L. D1 antagonists: safety, pharmacokinetics and D1 occupancy of NNC 01-0687 in healthy volunteers. American College of Neuropsychopharmacology, 32nd Annual meeting, Po 208: 1993. (Abstract).
38. Carlson H.E., Ippoliti A.F., Swerdloff R.S. Endocrine effects of acute and chronic cimetidine administration. Dig. Dis. Sci. 26: 428, 1981.
39. Delitala G., Stubbs W.A., Wass J.A., Jones A., Williams S., Besser G.M. Effects of the H2 receptor antagonist cimetidine on pituitary hormones in man. Clin. Endocrinol. (Oxf.) 11: 161, 1979.